# EDGAR Filing Document

**Accession Number:** 0001503274
**File Stem:** 0001503274-25-000095
**Filing Date:** 2025-9
**Character Count:** 56533
**Document Hash:** b3d15ea0baba5199a9f53b39e69ad739
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001503274-25-000095.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0001503274-25-000095

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250708

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250923

**DATE AS OF CHANGE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quanterix Corp
- **CENTRAL INDEX KEY:** 0001503274
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208957988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38319
- **FILM NUMBER:** 251333682

**BUSINESS ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821
- **BUSINESS PHONE:** 617-301-9400

**MAIL ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821

?xml version='1.0' encoding='ASCII'? qtrx-20250708

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

______________________________________

**FORM 8-K/A**

______________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 8, 2025**

_________________________________________________

**QUANTERIX CORPORATION**

(Exact name of registrant as specified in its charter)

_________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38319** | **20-8957988** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **900 Middlesex Turnpike** | |
| **Billerica, MA** | **01821** |
| (Address of principal executive offices) | (Zip Code) |

---

**(617) 301-9400**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading symbol(s):** | **Name of each exchange on which**<br>**registered:** |
| Common Stock, $0.001 par value per share | QTRX | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Explanatory Note**

On July 8, 2025, Quanterix Corporation, a Delaware corporation ("Quanterix"), filed a Current Report on Form 8-K (the "Original Report") to report the completion of its previously announced acquisition of Akoya Biosciences, Inc. a Delaware corporation ("Akoya"), on that same date. The acquisition was consummated pursuant to the terms of that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, by and among Quanterix, Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix, and Akoya.

This Amendment No. 1 to Current Report on Form 8-K amends the Original Report to include the pro forma financial information required under Items 9.01(b) and excluded from the Original Report in reliance on Item 9.01.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(a)Financial Statements of Business Acquired.

The historical financial statements of Akoya were previously reported in Post Effective Amendment No. 2 to the Registration Statement on Form S-4 filed by Quanterix on June 4, 2025 (File No. 333-284932) and are omitted in reliance on General Instruction B.3 to Form 8-K.

(b)Unaudited Pro Forma Financial Information

The unaudited pro forma condensed combined financial statements for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025 giving effect to the acquisition of Akoya are filed as Exhibit 99.1 to this Amendment No. 1 to the Current Report on Form 8-K and incorporated in this Item 9.01 by reference.

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Unaudited](exh991-proformafinancials.htm)[p](exh991-proformafinancials.htm)[ro](exh991-proformafinancials.htm)[f](exh991-proformafinancials.htm)[orma](exh991-proformafinancials.htm)[condensed combined](exh991-proformafinancials.htm)[f](exh991-proformafinancials.htm)[inancial](exh991-proformafinancials.htm)[s](exh991-proformafinancials.htm)[tatements of Quanterix Corporation and Akoya Biosciences, Inc. for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025.](exh991-proformafinancials.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: September 23, 2025 | **QUANTERIX CORPORATION** | **QUANTERIX CORPORATION** |
|  | **By:** | /s/ Vandana Sriram |
|  | **Name:** | Vandana Sriram |
|  | **Title:** | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION**

On July 8, 2025 (the "Closing Date"), Quanterix Corporation, a Delaware corporation (the "Company" or "Quanterix"), completed the transactions contemplated by the Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025 (the "Merger Agreement"), by and among the Company, Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Akoya Biosciences, Inc., a Delaware corporation ("Akoya"). On the Closing Date, Merger Sub merged with and into Akoya (the "Merger"), with Akoya surviving the Merger as a wholly owned subsidiary of the Company. The Merger was described in the Registration Statement on Form S-4 (File No. 333- 284932) filed with the U.S. Securities and Exchange Commission (the "SEC") on February 14, 2025, as amended by Post-Effective Amendments Nos. 1 and 2, filed on May 21, 2025 and June 4, 2025, respectively, and declared effective by the SEC on June 12, 2025 (as amended, the "Registration Statement").

Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of Akoya outstanding immediately prior to the Effective Time (other than (x) shares held as of the Effective Time by the Company, Merger Sub, any direct or indirect wholly owned subsidiary of the Company or Akoya or by Akoya as treasury shares and (y) shares as to which a holder properly demanded appraisal and did not withdraw or lose such claim for appraisal) was converted into the right to receive the following consideration: (a) 0.1470 (the "Exchange Ratio") of a fully paid and nonassessable share of common stock, par value $0.001 per share, of Quanterix (the shares so delivered in respect of each share of Akoya common stock, the "Per Share Stock Consideration") and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding and (b) $0.37 in cash without interest (the "Per Share Cash Consideration").

The accompanying unaudited pro forma condensed combined financial statements were prepared using the acquisition method of accounting in accordance with Financial Accounting Standards Board Accounting Standards Codification ("ASC") Topic 805 - *Business Combinations* ("ASC 805"). Under the acquisition method of accounting, the acquired identifiable tangible and intangible assets and liabilities assumed of Akoya are generally recognized based on their respective estimated fair values with any excess purchase price recognized as goodwill. Significant estimates and assumptions were used in determining the estimated purchase price and the estimated fair values of certain tangible and intangible assets acquired and liabilities assumed that are reflected in the unaudited pro forma condensed combined financial statements. The process of valuing the net assets of Akoya immediately prior to the business combination for purposes of presentation within this unaudited pro forma condensed combined financial information is preliminary. The pro forma adjustments are subject to modification based on the final determination of the fair value of the assets acquired and liabilities assumed and additional information that may become available. The Company is also in the process of performing a detailed review of Akoya's accounting policies in an effort to determine if differences in accounting policies require further adjustment or reclassification of Akoya's results of operations or assets or liabilities to conform to the Company's accounting policies and classification. As a result, the Company may subsequently identify additional differences in the accounting policies which could have a material impact on the unaudited pro forma condensed combined financial information. As the unaudited pro forma condensed combined financial statements have been prepared based on these preliminary estimates and policy review, the final amounts recorded may differ materially from the information presented.

The unaudited pro forma condensed combined financial statements give effect to the transaction as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheets of Quanterix and Akoya as of June 30, 2025, as if the Merger occurred on June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2025 and the year ended December 31, 2024 combines the historical consolidated statements of operations of Quanterix and Akoya as if the Merger occurred on January 1, 2024.

The unaudited pro forma condensed combined financial statements have been prepared using the audited consolidated financial statements of Quanterix for the year ended December 31, 2024, the unaudited consolidated financial statements of Quanterix as of and for the six months ended June 30, 2025, the audited financial statements

------

of Akoya for the year ended December 31, 2024, and unaudited consolidated financial information of Akoya as of and for the six months ended June 30, 2025.

The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X as amended by the final rule, Release 33-10786 "Amendments to Financial Disclosures about Acquired and Disposed Businesses" ("Article 11 of Regulation S-X"). Article 11 of Regulation S-X provides requirements to depict the accounting for the transaction ("Transaction Accounting Adjustment") and the option to present reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur. ("Management's Adjustments"). The Company has elected not to present Management's Adjustments and is only presenting Transaction Accounting Adjustments.

The unaudited pro forma condensed combined financial statements should be read in conjunction with Quanterix's and Akoya's historical financial statements (including each company's quarterly and annual reports, as separately filed with the SEC) and the accompanying notes herein to the unaudited pro forma condensed combined financial statements, which describe the underlying assumptions and estimates to the adjustments. The pro forma events are believed to be (i) directly attributable to the transaction, (ii) factually supportable, and (iii) with respect to the unaudited pro forma condensed combined statement of operations, expected to have a continuing effect on the combined results of Quanterix and Akoya. Management believes these adjustments to be reasonable based upon the preliminary assessment of the available information.

The unaudited pro forma condensed combined financial information presented is for illustrative purposes only and is not necessarily indicative of the financial position or results of earnings that would have been realized if the Merger had been completed on the dates set forth above, nor is it indicative of future results or financial position. The unaudited pro forma condensed combined financial statements presented herein do not reflect the cost of any integration activities, cost savings from synergies, or cost increases from dis-synergies.

------

**Unaudited Pro Forma Condensed Combined Balance Sheet**

**As of June 30, 2025**

**(in thousands)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Historical** | **Historical** | **Pro Forma** | **Pro Forma** | **Pro Forma** |
| | **Quanterix** | **Akoya, Reclassified <br>- Note 8** | **Transaction Accounting Adjustments** | **Note 5** | **Pro Forma Combined** |
| **ASSETS** | | | | | |
| **Current assets** | | | | | |
| Cash and cash equivalents | $132896 | $17835 | $(101036) | (a),(b),(d) | $49695 |
| Marketable securities | 128276 |  |  |  | 128276 |
| Accounts receivables, net of allowance for expected credit losses | 23549 | 9658 |  |  | 33207 |
| Inventory | 30142 | 23206 | 1294 | (j) | 54642 |
| Prepaid expenses and other current assets | 7254 | 3484 |  |  | 10738 |
| **Total current assets** | **322117** | **54183** | **(99742)** |  | **276558** |
| Restricted cash | 2641 | 691 |  |  | 3332 |
| Property and equipment, net | 15748 | 7247 | 4939 | (h) | 27934 |
| Goodwill |  | 18262 | 13489 | (a), (b), (c), (d), (f), (g), (h), (i), (j) | 31751 |
| Intangible assets, net | 16332 | 13132 | 72368 | (g) | 101832 |
| Operating lease right-of-use assets, net | 15710 | 3460 | (782) | (i) | 18388 |
| Financing lease right-of-use assets, net |  | 1130 | 61 | (i) | 1191 |
| Other non-current assets | 3061 | 437 |  |  | 3498 |
| **Total non-current assets** | **53492** | **44359** | **90075** |  | **187926** |
| **Total assets** | $**375609** | $**98542** | $**(9667)** |  | $**464484** |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |  |  |  |
| **Current liabilities** |  |  |  |  |  |
| Accounts payable | $9124 | $8053 | $— |  | $17177 |
| Accrued compensation and benefits | 9110 | 4174 |  |  | 13284 |
| Accrued expenses and other current liabilities | 15388 | 8583 | 8120 | (e) | 32091 |
| Deferred revenue | 9427 | 6185 |  |  | 15612 |
| Operating lease liabilities | 5153 | 2715 | (3) | (i) | 7865 |
| Finance lease liabilities |  | 443 | 7 | (i) | 450 |
| **Total current liabilities** | **48202** | **30153** | **8124** |  | **86479** |
| Long-term debt, net of debt discount |  | 76796 | (76796) | (b) |  |
| Contingent consideration liability |  | 3584 |  |  | 3584 |
| Deferred revenue, net of current portion | 1056 | 2550 |  |  | 3606 |
| Operating lease liabilities, net of current portion | 30381 | 2815 | (17) | (i) | 33179 |
| Financing lease liabilities, net of current portion |  | 537 | 34 | (i) | 571 |
| Non-current portion of contingent consideration | 2718 |  |  |  | 2718 |
| Other non-current liabilities | 794 | 180 | (125) | (k) | 849 |
| **Total non-current liabilities** | **34949** | **86462** | **(76904)** |  | **44507** |
| **Total liabilities** | **83151** | **116615** | **(68780)** |  | **130986** |
| **Stockholders' equity** |  |  |  |  |  |
| Common stock | 39 | 2 | 6 | (c), (d) | 47 |
| Additional paid-in capital | 813945 | 297261 | (248109) | (c), (d) | 863097 |
| Accumulated other comprehensive loss | (928) |  |  | (c) | (928) |
| Accumulated deficit | (520598) | (315336) | 307216 | (c), (e) | (528718) |
| **Total stockholders' equity** | **292458** | **(18073)** | **59113** |  | **333498** |
| **Total liabilities and stockholders' equity** | $**375609** | $**98542** | $**(9667)** |  | $**464484** |

---

------

**Unaudited Pro Forma Condensed Combined Statement of Operations**

**For the Six Months Ended June 30, 2025**

**(in thousands, except per share data)** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Historical** | **Historical** | **Pro Forma** | **Pro Forma** | **Pro Forma** |
| | **Quanterix** | **Akoya, Reclassified <br>- Note 8** | **Transaction Accounting Adjustments** | **Note 6** | **Pro Forma Combined** |
| **Revenues:** | | | | | |
| Product revenue | $37572 | $25945 | $— |  | $63517 |
| Service and other revenue | 15853 | 8883 |  |  | 24736 |
| Collaboration and license revenue | 1303 |  |  |  | 1303 |
| Grant revenue | 82 |  |  |  | 82 |
| **Total revenue** | **54810** | **34828** | **—** |  | **89638** |
| **Cost of goods sold and services:** |  |  |  |  |  |
| Cost of product revenue | 19059 | 9372 | (20) | (b),(f) | 28411 |
| Cost of service and other revenue | 8035 | 3838 | (14) | (b),(f) | 11859 |
| **Total costs of goods sold and services** | **27094** | **13210** | **(34)** |  | **40270** |
| **Gross profit** | **27716** | **21618** | **34** |  | **49368** |
| **Operating expenses:** |  |  |  |  |  |
| Research and development | 19117 | 11053 | 2749 | (a),(b),(f) | 32919 |
| Selling, general and administrative | 63812 | 35566 | (5470) | (a),(b),(c),(f) | 93908 |
| Other lease costs | 584 |  |  |  | 584 |
| Impairment and restructuring costs | 7670 |  |  |  | 7670 |
| **Total operating expenses** | **91183** | **46619** | **(2721)** |  | **135081** |
| **Loss from operations** | **(63467)** | **(25001)** | **2755** |  | **(85713)** |
| Interest income (expense), net | 5962 | (4468) | 3085 | (b),(d) | 4579 |
| Change in fair value of contingent consideration | 3894 | (266) |  |  | 3628 |
| Other income (expense), net | 108 | (111) |  |  | (3) |
| **Loss before income taxes** | **(53503)** | **(29846)** | **5840** |  | **(77509)** |
| Income tax (expense) benefit | 2986 | (55) | (24) | (e) | 2907 |
| **Net loss** | $**(50517)** | $**(29901)** | $**5816** |  | $**(74602)** |
| Net loss per common share, basic and diluted | $(1.30) | $(0.60) | $— |  | $(1.61) |
| Weighted-average common shares outstanding, basic and diluted | 38801 | 49788 | 7517 |  | 46318 |

---

------

**Unaudited Pro Forma Condensed Combined Statement of Operations**

**For the Year Ended December 31, 2024**

**(in thousands, except per share data)** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Historical** | **Historical** | **Pro Forma** | **Pro Forma** | **Pro Forma** |
| | **Quanterix** | **Akoya, Reclassified <br>- Note 8** | **Transaction Accounting Adjustments** | **Note 7** | **Pro Forma Combined** |
| **Revenues:** | | | | | |
| Product revenue | $79740 | $53027 | $— |  | $132767 |
| Service and other revenue | 51244 | 28645 |  |  | 79889 |
| Collaboration and license revenue | 4452 |  |  |  | 4452 |
| Grant revenue | 1985 |  |  |  | 1985 |
| **Total revenue** | **137421** | **81672** | **—** |  | **219093** |
| **Cost of goods sold and services:** |  |  |  |  |  |
| Cost of product revenue | 33304 | 22555 | 2466 | (b), (c), (g)  | 58325 |
| Cost of service and other revenue | 21013 | 9749 | (288) | (b),(g) | 30474 |
| **Total costs of goods sold and services** | **54317** | **32304** | **2178** |  | **88799** |
| **Gross profit** | **83104** | **49368** | **(2178)** |  | **130294** |
| **Operating expenses:** |  |  |  |  |  |
| Research and development | 31082 | 19202 | 5416 | (a), (b), (g) | 55700 |
| Selling, general and administrative | 101618 | 71350 | 8241 | (a), (b), (d), (g) | 181209 |
| Other lease costs | 3020 |  |  |  | 3020 |
| Impairment and restructuring costs |  | 6058 |  |  | 6058 |
| **Total operating expenses** | **135720** | **96610** | **13657** |  | **245987** |
| **Loss from operations** | **(52616)** | **(47242)** | **(15835)** |  | **(115693)** |
| Interest income (expense), net | 14655 | (7923) | 8450 | (b), (e) | 15182 |
| Change in fair value of contingent consideration |  | 512 |  |  | 512 |
| Other income (expense), net | (136) | (566) |  |  | (702) |
| **Loss before income taxes** | **(38097)** | **(55219)** | **(7385)** |  | **(100701)** |
| Income tax (expense) benefit | (434) | (146) | 43 | (f) | (537) |
| **Net loss** | $**(38531)** | $**(55365)** | $**(9512)** |  | $**(101238)** |
| Net loss per common share, basic and diluted | $(1.00) | $(1.12) | $— |  | $(2.21) |
| Weighted-average common shares outstanding, basic and diluted | 38367 | 49419 | 7517 |  | 45884 |

---

------

**NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION**

**1. Description of the Merger**

On July 8, 2025, Quanterix completed the transactions contemplated by the Merger Agreement, by and among the Company, Merger Sub, and Akoya. On the Closing Date, Merger Sub merged with and into Akoya, with Akoya surviving the Merger as a wholly owned subsidiary of the Company.

As a result of the Merger, each issued and outstanding share of Akoya as of immediately prior to the Effective Time of the Merger was converted into the right to receive the Per Share Stock Consideration and Per Share Cash Consideration. Any partial share as a result of the Exchange Ratio was rounded down to the nearest whole value, with the differential value paid to the shareholder in cash. Additionally, pursuant to the terms of the Merger Agreement and the governing plans and agreements (including existing employment agreements), equity awards issued by Akoya that were outstanding as of immediately prior to the Effective Time were treated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As of immediately prior to the Effective Time, each restricted stock unit in respect of shares of Akoya Common Stock (each, an "Akoya RSU") that was outstanding immediately prior to the Effective Time (a "Rollover RSU") was automatically converted into an award of restricted stock units with respect to shares of Quanterix Common Stock, with the number of shares of Quanterix Common Stock subject to each Rollover RSU equal to the product, rounded down to the nearest whole number of shares, of (i) the number of shares of Akoya Common Stock subject to such Akoya RSU immediately prior to the Effective Time and (ii) the Exchange Ratio. Such Rollover RSUs were otherwise subject to the same terms and conditions, including vesting, as were applicable to the relevant Akoya RSU immediately prior to the Effective Time, except that Akoya RSUs that, by their existing terms, provided for vesting acceleration triggered in connection with the Effective Time were so accelerated in accordance with such terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As of immediately prior to the Effective Time, each Rollover Option was automatically converted into an option to acquire shares of Quanterix Common Stock, with (i) the number of shares of Quanterix Common Stock subject to each Rollover Option equal to (rounding down to the nearest whole number of shares) the product of (a) the number of shares of Akoya Common Stock subject to the relevant Akoya Option as of immediately prior to the Effective Time and (b) the Exchange Ratio, and (ii) the per share exercise price for the shares of Quanterix Common Stock issuable upon exercise of each Rollover Option equal to (rounding up to the nearest whole cent) (a) the per share exercise price for the shares of Akoya Common Stock subject to the relevant Akoya Option as in effect immediately prior to the Effective Time, divided by (b) the Exchange Ratio. Such Rollover Options were otherwise subject to the same terms and conditions, including vesting, as were applicable to the relevant Akoya Option immediately prior to the Effective Time, except that Akoya Options that, by their existing terms, provided for vesting acceleration triggered in connection with the Effective Time were so accelerated in accordance with such terms.

**2. Basis of Presentation**

The unaudited pro forma condensed combined financial information and related notes are prepared in accordance with SEC Article 11 of Regulation S-X and present the combination of the historical financial information of Quanterix and Akoya adjusted to give effect to the business combination and the other events contemplated by the Merger Agreement.

The Merger will be accounted for under the acquisition method of accounting for business combinations pursuant to ASC 805. Quanterix is the accounting acquirer, as it is the entity which contributed both equity and cash to fund the transaction and beneficially owns 100% of the outstanding shares of Akoya's common stock. Under the acquisition method of accounting, Quanterix's assets and liabilities remain at their historical carrying values and Akoya's assets and liabilities will generally be recorded at their fair values measured as of the acquisition date under ASC 820 - *Fair Value Measurements* ("ASC 820"). The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

------

ASC 820 defines fair value, establishing the framework for measuring the fair value of any asset acquired or liability assumed under U.S. GAAP, expands disclosures for fair value measurements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value of the assets. Significant judgment is required in determining the preliminary fair values of identified intangible assets, property and equipment, inventory, deferred revenue, and certain other assets and liabilities. These preliminary valuations of assets acquired and liabilities assumed are determined using market, income, and cost approaches from the perspective of a market participant, which requires estimates and assumptions including, but not limited to, estimating future cash flows in addition to developing the appropriate market discount rates and obtaining available market pricing for comparable assets. Further, it assumes the highest and best use by the market participants and may not reflect management's intended use for those assets. The final amounts of assets acquired and liabilities assumed will be dependent on a number of factors, which are not known or predicted with certainty at this time. As such, the final accounting for the acquisition may materially change the values recognized for the assets acquired and liabilities assumed and, as a result, materially change the unaudited pro forma financial information.

The historical consolidated financial statements of Quanterix and Akoya were prepared in accordance with U.S. GAAP and presented in U.S. dollars.

The accompanying unaudited pro forma financial information illustrates the combination of the financial information of Quanterix and Akoya adjusted to give effect to the business combination and other events contemplated by the Merger Agreement. The pro forma adjustments required to reflect the acquired assets and assumed liabilities are generally based on the estimated fair values of Akoya's assets and liabilities as of June 30, 2025. The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2025 and the year ended December 31, 2024 give effect to the Akoya acquisition as though it had occurred on January 1, 2024.

The unaudited pro forma financial information is not necessarily indicative of what the actual results of operations and financial position would have been had the Merger taken place on the dates indicated, nor are they indicative of the future consolidated results of operations or financial position of Quanterix, and they are based on the information available at the time of their preparation. Actual results may differ materially from the assumptions within the unaudited pro forma condensed combined financial information.

**Accounting Policies and Reclassification**

The accounting policies used in the preparation of the unaudited pro forma condensed combined financial statements are those described in Quanterix's Annual Report on Form 10-K, as filed with the SEC on March 17, 2025. Quanterix is in the process of performing a detailed review of Akoya's accounting policies in an effort to determine if differences in accounting policies require further adjustment or reclassification of Akoya's results of operations or assets or liabilities to conform to the Company's accounting policies and classification. As a result, the Company may subsequently identify additional differences in the accounting policies which could have a material impact on the unaudited pro forma condensed combined financial information. The adjustments described herein were necessary to ensure the comparability in the unaudited pro forma financial information.

------

**3. Consideration Transferred**

The following table presents the fair value of the consideration transferred for the Merger, determined as of July 8, 2025 (in thousands, except for the Exchange Ratio and stock price):

---

| | |
|:---|:---|
| **(in thousands, except for exchange ratio and stock price):** | |
| Akoya common stock outstanding as of July 7, 2025 | 49957 |
| Akoya Restricted Stock Units outstanding as of July 7, 2025 | 360 |
| Akoya Options outstanding as of July 7, 2025 | 829 |
| **Total Akoya equity instruments to be converted** | **51146** |
| Exchange Ratio | 0.147 |
| **Total shares of Quanterix common stock to be issued** | **7518** |
| Quanterix stock price | $6.54 |
| **Fair value of Quanterix common stock transferred to Akoya shareholders** <sup>(a)</sup> | $**49160** |
| Cash consideration paid <sup>(b)</sup> | $18924 |
| Cash paid in lieu of fractional shares issued by Quanterix <sup>(c)</sup> | $11 |
| Cash paid for debt extinguishment <sup>(d)</sup> | $82101 |
| **Total fair value of consideration transferred** | $**150196** |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Represents the stock consideration paid to Akoya stockholders at an adjusted Exchange Ratio of 0.147 and using the last reported sale price of Quanterix shares on the Nasdaq Global Market on July 7, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Represents cash consideration paid to Akoya stockholders of $0.37 per share of Akoya common stock, per the Merger Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Represents the fair value of the fractional shares paid in cash to Akoya stockholders as purchase consideration upon the effectiveness of the Merger.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Represents the repayment of Akoya's long-term debt upon the effectiveness of the Merger.

------

**4. Preliminary Acquisition Accounting**

The recognition of the acquired assets and assumed liabilities with respect to the Merger is based upon management's estimates of and assumptions related to the fair values of assets to be acquired and liabilities to be using currently available information. The final purchase price allocation will be determined when the Company has gathered the information necessary to complete the detailed valuations and related calculations. Due to the fact that the unaudited pro forma condensed combined financial statements have been prepared based on preliminary estimates, the final acquisition accounting and the resulting effect on the combined entity's financial position and results of operations may differ materially from the pro forma amounts included herein.

The following table sets forth a preliminary estimate of the amounts to be recognized for the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess purchase consideration recorded to goodwill, as if the Merger occurred on June 30, 2025:

---

| | |
|:---|:---|
| **(in thousands):** | **Amount** |
| Cash and cash equivalents | $17835 |
| Accounts receivable, net of allowance for expected credit losses | 9658 |
| Inventory | 24500 |
| Prepaid expenses and other current assets | 3484 |
| Restricted cash | 691 |
| Property and equipment, net | 12186 |
| Intangible assets, net | 85500 |
| Operating lease right of use assets, net | 2678 |
| Finance lease right of use assets, net | 1191 |
| Other non-current assets | 437 |
| **Total assets acquired** | $**158160** |
| Accounts payable | 8053 |
| Accrued expenses and other current liabilities | 12757 |
| Deferred revenue | 6185 |
| Operating lease liabilities | 2712 |
| Finance lease liabilities | 450 |
| Contingent consideration liability | 3584 |
| Deferred revenue, net of current portion | 2550 |
| Operating lease liabilities, net of current portion | 2798 |
| Finance lease liabilities, net of current portion | 571 |
| Other non-current liabilities | 55 |
| **Total liabilities assumed** | **39715** |
| **Total assets acquired in excess of liabilities assumed** | **118445** |
| **Goodwill** | **31751** |
| **Total consideration transferred** | $**150196** |

---

------

**5. Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2025**

a) Payment of $11 thousand to Akoya's shareholders for fractional shares; refer to Note 3c.

b) Represents the elimination of Akoya's long-term debt as part of the purchase price. Quanterix paid off Akoya's long term debt directly, therefore this debt is not part of the liabilities assumed, but rather is considered part of the purchase price.

---

| | |
|:---|:---|
| **(in thousands):** | **Amount** |
| Carrying value of long-term debt | $76796 |
| Prepayment penalty and exit fee on long-term debt | 5306 |
| Total payments related to long-term debt | $82102 |

---

c) Elimination of Akoya's historical stockholders' equity of $18,073 thousand

d) Recording estimated purchase consideration of $150,196 thousand, of which $82,101 thousand was already recorded above in entry (b) through the elimination of debt. $8 thousand is included in common stock as par value of 7,770 shares outstanding at a par value of $0.001 per share with the balance of $150,189 thousand included in additional paid-in capital, and cash of $18,936 thousand for the payment of Akoya outstanding and fractional shares.

---

| | | | |
|:---|:---|:---|:---|
| **(in thousands, except for exchange ratio and stock price):** | **Shares** | **Price / Exchange Value** | **Value** |
| Common Shares issued for consideration | 7341938 | $6.54 | $48016 |
| Common Shares issued for Accelerated RSUs (Settled) | 52925 | $6.54 | 346 |
| Options Converted to Quanterix common shares | 121866 | $6.54 | 797 |
| Cash for Akoya outstanding shares | 49956551 | $0.37 | 18484 |
| Cash to settled RSU holders |  |  | 133 |
| Cash to Options holders |  |  | 308 |
| Cash for fractional shares |  |  | 11 |
| **Total consideration** |  |  | **68095** |
| Akoya debt paid off by Quanterix |  |  | 82101 |
| **Total consideration transferred** |  |  | $**150196** |

---

e) Reflects the accrual of Quanterix's non-recurring transaction costs of $8,120 thousand related to the Merger, including fees expected to be paid for financial advisors, legal services, and professional accounting services. The unaudited pro forma condensed combined balance sheet as of June 30, 2025 does not reflect $3,157 thousand of consulting fees and legal fees incurred by Akoya subsequent to June 30, 2025 as a result of the Merger .

f) Represents the elimination of $18,262 thousand of existing goodwill of Akoya and the preliminary recognition of $31,751 thousand of goodwill arising from the Merger, which is not expected to be deductible for tax purposes.

------

g) Represents the elimination of $13,132 thousand of existing intangible assets of Akoya, and preliminary recognition of $85,500 thousand of identifiable intangible assets attributable to the transaction.

---

| | | | |
|:---|:---|:---|:---|
| **(in thousands):** | **Fair Value** | **Estimated useful lives** | **Amortization expense for the six months ended June 30, 2025** |
| Customer Relationships | $2200 | 9 | $122 |
| Developed Technology  | 59200 | 9.5 | 3116 |
| In-Process Research & Development (IPR&D) | 24100 |  |  |
| &nbsp;&nbsp;**Total** | $**85500** |  | $**3238** |

---

These preliminary estimates of fair value and estimated useful lives will likely differ from the final amounts Quanterix will calculate after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying unaudited pro forma condensed combined financial statements. A 10% change in the valuation of intangible assets would cause a corresponding increase or decrease to goodwill and a resulting increase or decrease in the amortization expense of approximately $611 thousand for the six months ended June 30, 2025, and $1,221 thousand for the year ended December 31, 2024, based on a weighted average useful life of 6.8 years.

h) Represents a property and equipment step-up in fair value of $4,939 thousand as follows:

---

| | |
|:---|:---|
| **(in thousands):** | **Amount** |
| Property, plant and equipment | $2057 |
| Demo Inventory | 2882 |

---

i) Represents adjustments to remeasure material acquired lease liabilities and right-of-use assets in accordance with ASC 842 - Leases, as follows:

---

| | |
|:---|:---|
| **(in thousands):** | **Amount** |
| Operating lease right-of-use assets | $(782) |
| Financing lease right-of-use assets, net | 61 |
| Operating lease liabilities | (3) |
| Current portion of financing lease liabilities | 7 |
| Operating lease liabilities, net of current portion | (17) |
| Financing lease liabilities, net of current portion | 34 |

---

j) Represents an inventory step-up in fair value of $1,294 thousand.

k) Represents a decrease to the deferred tax liability associated with the preliminary fair value adjustments for the acquired inventory and identifiable intangible assets that are estimated to result in future taxable income. The majority of the assets acquired and liabilities assumed would be offset with pre-existing deferred tax assets and a valuation allowance. Accordingly, a $125 thousand net decrease to the deferred tax liability was recorded.

------

**6. Adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations for the Six Months Ended June 30, 2025**

a) Represents the elimination of historical intangible assets amortization expense and recognition of amortization expense related to intangible assets recognized as part of the Merger:

---

| | |
|:---|:---|
| **(in thousands):** | **Six Months Ended June 30, 2025** |
| Elimination of historical intangible assets amortization expense classified within selling, general and administrative | $(1155) |
| Recognition of amortization expense within selling, general and administrative | 122 |
| **Selling, general and administrative, net impact** | $**(1033)** |

---

---

| | |
|:---|:---|
| **(in thousands):** | **Six Months Ended June 30, 2025** |
| Elimination of historical intangible assets amortization expense classified within research and development | $(272) |
| Recognition of amortization expense within research and development | 3116 |
| **Research and development, net impact** | $**2844** |

---

The above adjustments relate to amortization of intangible assets recognized at their estimated fair values and is based on the useful life of such assets outlined in Note 5g.

b) Represents the following adjustments associated with the elimination of Akoya's historical lease expense, and the recognition of the estimated lease expense based on the remeasured material acquired lease liabilities and ROU assets:

---

| | |
|:---|:---|
| **(in thousands):** | **Six Months Ended June 30, 2025** |
| Cost of service and other revenue | $4 |
| Cost of product revenue | (4) |
| Selling, general and administrative | (77) |
| Research and development | 8 |
| Interest expense | (17) |

---

------

c) Represents the following adjustments to selling, general and administrative expenses:

---

| | |
|:---|:---|
| **(in thousands):** | **Six Months Ended June 30, 2025** |
| Transaction costs expected to be incurred (i) | $(4701) |
| Adjustments to stock-based compensation expense due to replacement awards issued (ii) | 505 |
| **Selling, general and administrative, net impact** | $**(4196)** |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i)As the transaction is assumed to have occurred January 1, 2024, Quanterix's non-recurring transaction costs of $4,701 thousand related to the Merger, including fees expected to be paid for financial advisors, legal services, and professional accounting services, are assumed to have been incurred in the year ended December 31, 2024.

ii)Represents future employee services associated with rollover stock option awards that will be expensed as stock-based compensation on a straight-line basis over the remaining service periods of the replacement awards.

d) Represents the elimination of $4,946 thousand of Akoya's historical interest expense on long-term debt . Additionally, the adjustment includes an interest income reduction of $1,844 thousand associated with the interest foregone by Quanterix as a result of the assumed settlement of Akoya's debt as of the acquisition date, and a reduction of interest expense on finance leases by $17 thousand.

e) Reflects an adjustment to the provision for income taxes as a result of the estimated income tax effects of the pro forma transaction accounting adjustments herein. The adjustment was calculated using a blended statutory income tax rate of 24.4%. The blended statutory tax rate is not necessarily indicative of the effective tax rate following the Merger.

f) Represents the adjustment to depreciation expense related to fixed assets recognized as part of the Merger:

---

| | |
|:---|:---|
| **(in thousands):** | **Six Months Ended June 30, 2025** |
| Cost of product revenue | $(16) |
| Cost of service and other revenue | (18) |
| Selling, general and administrative | (164) |
| Research and development | (104) |

---

------

**7. Adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations for the Year Ended December 31, 2024**

a) Represents the elimination of historical intangible assets amortization expense and recognition of amortization expense related to intangible assets recognized as part of the Merger:

---

| | |
|:---|:---|
| **(in thousands):** | **Year Ended December 31, 2024** |
| Elimination of historical intangible assets amortization expense classified within selling, general and administrative | $(2310) |
| Recognition of amortization expense within selling, general and administrative | 244 |
| **Selling, general and administrative, net impact** | $**(2066)** |

---

---

| | |
|:---|:---|
| **(in thousands):** | **Year Ended December 31, 2024** |
| Elimination of historical intangible assets amortization expense classified within research and development | $(543) |
| Recognition of amortization expense within research and development | 6232 |
| **Research and development, net impact** | $**5689** |

---

The above adjustments relate to amortization of intangible assets recognized at their estimated fair values and is based on the useful life of such assets outlined in Note 5g.

b) Represents the following adjustments associated with the elimination of Akoya's historical lease expense and the recognition of the estimated lease expense based on the remeasured material acquired lease liabilities and ROU assets:

---

| | |
|:---|:---|
| **(in thousands):** | **Year Ended December 31, 2024** |
| Cost of service and other revenue | $6 |
| Cost of product revenue |  |
| Selling, general and administrative | 6 |
| Research and development | 11 |
| Interest expense | (27) |

---

c) Represents an adjustment to increase cost of product revenue by $2,665 thousand for the year ended December 31, 2024, as it is expected that the fair value step-up in inventory will result in an increase to cost of goods sold as the existing inventory is expected to be sold within one year of the acquisition.

------

d) Represents the following adjustments to selling, general and administrative expenses:

---

| | |
|:---|:---|
| **(in thousands):** | **Year Ended December 31, 2024** |
| Transaction costs expected to be incurred (i) | $10477 |
| Adjustments to stock-based compensation expense due to replacement awards issued (ii) | 289 |
| **Selling, general and administrative, net impact** | $**10766** |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i)Reflects Quanterix's non-recurring transaction costs of $10,477 thousand related to the Merger, including fees expected to be paid for financial advisors, legal services, and professional accounting services.

ii)Represents future employee services associated with rollover stock awards that will be expensed as stock-based compensation on a straight-line basis over the remaining service periods of the replacement awards.

e) Represents the elimination of $10,321 thousand of Akoya's historical interest expense on long-term debt. Additionally, the adjustment includes an interest income reduction of $1,844 thousand associated with the interest foregone by Quanterix as a result of the assumed settlement of Akoya's debt as of the acquisition date, and a reduction of interest expense on finance leases by $27 thousand.

f) Reflects an adjustment to the provision for income taxes as a result of the estimated income tax effects of the pro forma transaction accounting adjustments herein. The adjustment was calculated using a blended statutory income tax rate of 24.4%. The blended statutory tax rate is not necessarily indicative of the effective tax rate following the Merger.

g) Represents the adjustment to depreciation expense related to fixed assets recognized as part of the Merger:

---

| | |
|:---|:---|
| **(in thousands):** | **Year Ended December 31, 2024** |
| Cost of product revenue | $(189) |
| Cost of service and other revenue | (294) |
| Selling, general, and administrative | (465) |
| Research and development | (284) |

---

------

**8. Reclassification Adjustments** 

The tables below represent the reclassification adjustments for certain financial statement line items as reported by Akoya under U.S. GAAP, to align with the expected presentation within Quanterix's Consolidated Statements of Operations and Consolidated Balance Sheets post-Merger. Those balances not specifically referenced below have been presented within the equivalent Quanterix caption. Some amounts may not match the Akoya historical financial statement due to rounding.

------

**Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2025:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(in thousands):** | **Akoya - Historical** | **Reclassification** | **Notes** | **Akoya - As Reclassified** |
| **ASSETS** | | | | |
| **Current assets** | | | | |
| Cash and cash equivalents | $17835 | $— |  | $17835 |
| Marketable securities |  |  |  |  |
| Accounts receivables, net of allowance for expected credit losses | 9658 |  |  | 9658 |
| Inventory | 23206 |  |  | 23206 |
| Prepaid expenses and other current assets | 3484 |  |  | 3484 |
| **Total current assets** | **54183** | **—** |  | **54183** |
| Restricted cash | 691 |  |  | 691 |
| Property and equipment, net | 6329 | 918 | (c) | 7247 |
| Demo inventory, net | 918 | (918) | (c) |  |
| Goodwill | 18262 |  |  | 18262 |
| Intangible assets, net | 13132 |  |  | 13132 |
| Operating lease right-of-use assets, net | 3460 |  |  | 3460 |
| Financing lease right-of-use assets, net | 1130 |  |  | 1130 |
| Other non-current assets | 437 |  |  | 437 |
| **Total assets** | $**98542** | $**—** |  | $**98542** |
| **Current liabilities** |  |  |  |  |
| Accounts payable | $8053 | $— |  | $8053 |
| Accrued compensation and benefits |  | 4174 | (b) | 4174 |
| Accrued expenses and other current liabilities | 12757 | (4174) | (b) | 8583 |
| Deferred revenue | 6185 |  |  | 6185 |
| Operating lease liabilities | 2715 |  |  | 2715 |
| Finance lease liabilities | 443 |  |  | 443 |
| **Total current liabilities** | **30153** | **—** |  | **30153** |
| Long-term debt, net of debt discount | 76796 |  |  | 76796 |
| Contingent consideration liability, net of current portion | 3584 |  |  | 3584 |
| Deferred revenue, net of current portion | 2550 |  |  | 2550 |
| Operating lease liabilities, net of current portion | 2815 |  |  | 2815 |
| Financing lease liabilities, net of current portion | 537 |  |  | 537 |
| Deferred tax liability, net | 140 | (140) | (a) |  |
| Other liabilities | 40 | (40) | (a) |  |
| Other non-current liabilities |  | 180 | (a) | 180 |
| **Total liabilities** | **116615** | **—** |  | **116615** |
| **Stockholders' equity** |  |  |  |  |
| Common stock | 2 |  |  | 2 |
| Additional paid-in capital | 297261 |  |  | 297261 |
| Accumulated other comprehensive loss |  |  |  |  |
| Accumulated deficit | (315336) |  |  | (315336) |
| **Total stockholders' equity** | **(18073)** | **—** |  | **(18073)** |
| **Total liabilities and stockholders' equity** | $**98542** | $**—** |  | $**98542** |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Represents reclassification of $140 thousand from deferred tax liability, net and $40 thousand from other liabilities, both to other non-current liabilities to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Represents reclassification of $4,174 thousand to break out accrued compensation and benefits from accrued expenses and other current liabilities to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Represents reclassification of $918 thousand of demo inventory to property and equipment, net to conform to Quanterix's presentation.

------

**Unaudited Pro Forma Condensed Combined Statement of Operations for the Six Months Ended June 30, 2025:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(in thousands):** | **Akoya - Historical** | **Reclassification** | **Notes** | **Akoya - As Reclassified** |
| **Revenues:** | | | | |
| Product revenue | $25945 | $— |  | $25945 |
| Service and other revenue | 8883 |  |  | 8883 |
| **Total revenue** | **34828** | **—** |  | **34828** |
| **Cost of goods sold and services:** |  |  |  |  |
| Cost of product revenue | 9290 | 82 | (a),(c) | 9372 |
| Cost of service and other revenue | 4469 | (631) | (a) | 3838 |
| **Total costs of goods sold and services** | **13759** | **(549)** |  | **13210** |
| **Gross profit** | **21069** | **549** |  | **21618** |
| **Operating expenses:** |  |  |  |  |
| Research and development | 11325 | (272) | (c) | 11053 |
| Selling, general and administrative | 34745 | 821 | (a) | 35566 |
| Impairment and restructuring |  |  |  |  |
| Change in fair value of contingent consideration | 266 | (266) | (d) |  |
| Impairment |  |  |  |  |
| Restructuring |  |  |  |  |
| **Total operating expenses** | **46336** | **283** |  | **46619** |
| **Loss from operations** | **(25267)** | **266** |  | **(25001)** |
| Interest expense | (5007) | 5007 | (b) |  |
| Interest income (expense), net | 539 | (5007) | (b) | (4468) |
| Change in fair value of contingent consideration |  | (266) | (d) | (266) |
| Other income (expense), net | (111) |  |  | (111) |
| **Loss before income taxes** | **(29846)** | **—** |  | **(29846)** |
| Income tax (expense) benefit | (55) |  |  | (55) |
| **Net loss** | $**(29901)** | $**—** |  | $**(29901)** |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Represents the reclassification of shipping and handling costs for product sales of $109 thousand from cost of product revenue and $631 thousand from cost of service and other revenue to selling, general and administrative to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Represents the reclassification of $5,007 thousand from interest expense to interest income (expense), net to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Represents the reclassification of Akoya's amortization of capitalized software costs of $272 thousand from research and development to cost of product revenue to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Represents the reclassification of the change in fair value of contingent consideration out of total operating expenses to conform to Quanterix's presentation.

------

**Unaudited Pro Forma Condensed Combined Statement of Operations for the Year Ended December 31, 2024:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(in thousands):** | **Akoya - Historical** | **Reclassification** | **Notes** | **Akoya - As Reclassified** |
| **Revenues:** | | | | |
| Product revenue | $53027 | $— |  | $53027 |
| Service and other revenue | 28645 |  |  | 28645 |
| **Total revenue** | **81672** | **—** |  | **81672** |
| **Cost of goods sold and services:** |  |  |  |  |
| Cost of product revenue | 22039 | 516 | (a),(d) | 22555 |
| Cost of service and other revenue | 11755 | (2006) | (a) | 9749 |
| **Total costs of goods sold and services** | **33794** | **(1490)** |  | **32304** |
| **Gross profit** | **47878** | **1490** |  | **49368** |
| **Operating expenses:** |  |  |  |  |
| Research and development | 19745 | (543) | (d) | 19202 |
| Selling, general and administrative | 69317 | 2033 | (a) | 71350 |
| Impairment and restructuring |  | 6058 | (b) | 6058 |
| Change in fair value of contingent consideration | (512) | 512 | (e) |  |
| Impairment | 2971 | (2971) | (b) |  |
| Restructuring | 3087 | (3087) | (b) |  |
| **Total operating expenses** | **94608** | **2002** |  | **96610** |
| **Loss from operations** | **(46730)** | **(512)** |  | **(47242)** |
| Interest expense | (10429) | 10429 | (c) |  |
| Interest income (expense), net | 2506 | (10429) | (c) | (7923) |
| Change in fair value of contingent consideration |  | 512 | (e) | 512 |
| Other income (expense), net | (566) |  |  | (566) |
| **Loss before income taxes** | **(55219)** | **—** |  | **(55219)** |
| Income tax (expense) benefit | (146) |  |  | (146) |
| **Net loss** | $**(55365)** | $**—** |  | $**(55365)** |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Represents the reclassification of shipping and handling costs for product sales of $27 thousand from cost of product revenue and $2,006 thousand from cost of service and other revenue to selling, general and administrative to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Represents the reclassification of $2,971 thousand from impairment and $3,087 thousand from restructuring to impairment and restructuring to confirm to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Represents the reclassification of $10,429 thousand from interest expense to interest income (expense), net to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Represents the reclassification of Akoya's amortization of capitalized software costs of $53 thousand from research and development to cost of product revenue to conform to Quanterix's presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Represents the reclassification of the change in fair value of contingent consideration out of total operating expenses to conform to Quanterix's presentation.

<br>